Technetium (99mTc) exametazime
 | |
| Clinical data | |
|---|---|
| License data | |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C13H25N4O3Tc |
| Molar mass | 384.3655 g/mol g·mol−1 |
| (verify) | |
Technetium (99mTc) exametazime is a radiopharmaceutical sold under the trade name Ceretec, and is used for the detection of altered regional cerebral perfusion in stroke[1] and other cerebrovascular diseases. It can also be used for the labelling of leukocytes to localise intra-abdominal infections[2] and inflammatory bowel disease.[3] Exametazime (the part without technetium) is sometimes referred to by its chemical name of hexamethylpropyleneamine oxime or HMPAO.
Chemistry
The drug consists of two of the three stereoisomers of hexametazime (HMPAO), one of which is shown here, the other being its enantiomer.[4] The third stereoisomer is the meso form. Exametazime acts as a chelating agent for the radioisotope technetium-99m.
References
- ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 2307169, please use {{cite journal}} with
|pmid=2307169instead. - ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 7489945, please use {{cite journal}} with
|pmid=7489945instead. - ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 1804909, please use {{cite journal}} with
|pmid=1804909instead. - ^ Monography in the European Pharmacopoeia
External links
- European Association of Nuclear Medicine: Ceretec[dead link]
- GE Healthcare: Ceretec
- Exametazime ligand: CID 9552071 from PubChem
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |